Senescent-cell clearance
FOXO4-DRI was designed to push selected senescent cells toward apoptosis by disrupting FOXO4–p53 binding.
Explore the research →CELLULAR SENESCENCE & SENOLYTIC RESEARCH
FOXO4-DRI
An experimental senolytic peptide designed to target senescent cells, making it a closely watched idea in cellular ageing research.
Cellular senescenceSenolyticsAgeing biology
Compelling preclinical senolytic research; no established human treatmentFOXO4-DRI has produced striking experimental results in senescent-cell models and aged animals. Human therapeutic efficacy and safety remain unestablished.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in FOXO4-DRI?
FOXO4-DRI attracts attention because it targets one of ageing research's biggest ideas: removing senescent cells that have stopped dividing but continue to disrupt surrounding tissue. In animal models, that approach has improved several measures of tissue function, which explains the intense longevity interest.
Physical resilience
Early animal work reported improvements in markers of tissue homeostasis and physical function.
Explore the research →Brain ageing
Recent research explores vascular and brain-ageing consequences of senescent-cell clearance.
Explore the research →Longevity research
Senolytics are being studied as a way to alter age-related tissue dysfunction.
Explore the research →THE SCIENCE BIT
Interrupting a survival interaction in senescent cells.
Senescent cells have stopped dividing but can remain active. FOXO4-DRI was designed to disrupt the interaction between FOXO4 and p53, proteins involved in how these cells survive.
Experimental studies report increased death of selected senescent cells. That is a specific senolytic research strategy, not an established way to reverse ageing in people.
See the studies & trials →- FOXO4
- A protein involved in cell survival
- p53
- Cell-stress and death regulation
- Interaction disruption
- The experimental design
How this connects to the research
Preclinical senolytic evidence; human benefit and safety remain unestablished.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where FOXO4-DRI connects with the body
These are the tissues and biological systems behind the interest in FOXO4-DRI.
- Cell nucleus
- The protein interaction.
- Senescent cells
- The intended research target.
- Tissue models
- Experimental homeostasis studies.
The research behind the interest
Senescent-cell clearance
FOXO4-DRI was designed to push selected senescent cells toward apoptosis by disrupting FOXO4–p53 binding.
The concept has been demonstrated in cells and animal models, not as an established human treatment.
Strong preclinical evidenceExplore the studies →Physical resilience
Early animal work reported improvements in markers of tissue homeostasis and physical function.
These findings have not yet been demonstrated in controlled human trials.
Preclinical evidenceExplore the studies →Brain ageing
Recent research explores vascular and brain-ageing consequences of senescent-cell clearance.
This remains experimental and should not be presented as a cognitive treatment.
Emerging preclinical evidenceExplore the studies →Longevity research
Senolytics are being studied as a way to alter age-related tissue dysfunction.
FOXO4-DRI has not been shown to extend human lifespan or healthspan.
Preclinical researchExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableTargeted apoptosis of senescent cells restores tissue homeostasis ↗
Senescent cell systems and aged/chemotoxicity mouse models
Disrupting FOXO4–p53 selectively reduced senescent-cell viability and improved measures of tissue homeostasis in mice.
FOXO4-DRI and endothelial-cell senescence ↗
Senescent endothelial-cell models
FOXO4-DRI promoted apoptosis through p53-linked signalling in experimental endothelial cells.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceEarly
1/5 evidence depth
No established controlled human therapeutic evidence was identified.
✓
Clinical efficacyEarly
1/5 evidence depth
Clinical efficacy in people is unproven.
◇
Safety evidenceEarly
1/5 evidence depth
Human pharmacokinetics, dosing and long-term safety are not established.
⌁
Preclinical evidenceExtensive
5/5 evidence depth
Multiple mechanistic and animal studies support senolytic activity.
HOW TO READ THESE SCORESExtensive preclinical evidence · early human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
FOXO4-DRI research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01Cellular senescence
RESEARCH AREA 02Senolytics
RESEARCH AREA 03Ageing biology
RESEARCH AREA 04Tissue function
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with FOXO4-DRI
Longevity communities focus on senescent-cell clearance, physical resilience and cognitive ageing.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Clearing senescent cells
The senolytic idea attracts people interested in removing cells associated with ageing biology. This is a specific experimental strategy; feeling better after a course cannot show that targeted cells were cleared.
- What makes a report informative
- The model studied and how senescence was actually measured.
- What can muddy the picture
- Preclinical cell clearance is not established human treatment efficacy.
Physical vitality and tissue resilience
People hope that changing senescent-cell burden might translate into better recovery or physical function. Those downstream benefits need their own evidence rather than being assumed from the mechanism.
- What makes a report informative
- Specific functional outcomes and their persistence.
- What can muddy the picture
- Normal variation, rest and concurrent compounds can explain a subjective reset.
Brain and healthy-ageing goals
Interest extends to cognitive preservation and longer healthy life. These are long-term clinical questions that cannot be answered by a short-term anecdote or an ageing-biomarker claim.
- What makes a report informative
- Human clinical outcomes rather than broad rejuvenation language.
- What can muddy the picture
- Human benefit and safety remain unestablished for this experimental peptide.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Senescent-cell clearance
The concept has been demonstrated in cells and animal models, not as an established human treatment.
Evidence context: Strong preclinical evidence
Physical resilience
These findings have not yet been demonstrated in controlled human trials.
Evidence context: Preclinical evidence
Brain ageing
This remains experimental and should not be presented as a cognitive treatment.
Evidence context: Emerging preclinical evidence
Longevity research
FOXO4-DRI has not been shown to extend human lifespan or healthspan.
Evidence context: Preclinical research
The biological rationale
Senescent cells have stopped dividing but can remain active. FOXO4-DRI was designed to disrupt the interaction between FOXO4 and p53, proteins involved in how these cells survive.
Experimental studies report increased death of selected senescent cells. That is a specific senolytic research strategy, not an established way to reverse ageing in people.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
No validated human dose, route, cycle or therapeutic protocol has been established.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Preclinical senolytic context
Preclinical · no established human treatment scheduleThe key FOXO4-DRI work is preclinical. Animal amounts, delivery routes and senescent-cell findings do not establish a human titration, cycling schedule or safety profile. Amounts remain manual; no senolytic course is generated.
Form and route: Laboratory and animal senolytic experiments
The planner keeps amounts and repeat patterns blank for this compound. Use its formulation guide to record an independently specified schedule.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
Removing cells is a powerful biological intervention
What the current evidence saysSenescence also has normal roles in wound healing and tumour suppression. Selectivity, tissue effects, human pharmacology and long-term consequences require clinical evidence before benefits can be assumed.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
5 sourcesSources used on this profile
Original publicationTargeted apoptosis of senescent cells restores tissue homeostasisJournal / DOI ↗Original publicationFOXO4-DRI and endothelial-cell senescenceJournal / DOI ↗Bibliographic recordFOXO4-DRI and endothelial-cell senescencePubMed ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesDrugs@FDA ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine identified for this use
FOXO4-DRI is presented here for research context. Availability online does not establish medicine quality, safety or efficacy.
MHRA products database ↗No FDA-approved therapeutic product identified for this use
Published research and commercial availability are separate from regulatory approval.
Drugs@FDA ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.